ImmunoCellular Therapeutics (IMUC.OB) New Data from PI Glioblastoma Multiforme Trial at ASCO
100% of Patients in Study express at least 3 Antigens targeted By ICT-107; validating positive correlation between targeting stem cells and survival
IMUC.OB presented new data from the PI clinical trial of ICT-107, the lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM).
- The abstract titled, “Glioma-associated antigens associated with prolonged survival in a phase I study of ICT-107 for patients with newly diagnosed glioblastoma” (Abstract #2042) will show that there is a correlation between the immunological response that ICT-107 generated in the form of antigens and both progression-free and overall survival.
These observations suggest that targeting antigens highly expressed by cancer stem cells (CSCs) is a promising strategy for treating patients with glioblastoma. Tumor analyses for expression of the 6 antigens targeted by ICT-107 – HER-2, TRP-2, gp100, MAGE1, IL-13Rα2, and AIM-2 – revealed all patients exhibited at least 3 of these antigens and 75% exhibited all 6.
The bottom Line: Patients who demonstrated immunological response to vaccination with ICT-107 had longer PFS compared to non-responders. Responders also exhibited a trend toward longer OS. Patients who had recurrences after vaccination exhibited decreased levels of CD133, a biomarker of CSCs. In contrast, previous studies demonstrated an increase in CD133 expression in patients who underwent treatment with radiation and chemotherapy. This new data follows previously announced two-year results showing an overall survival (OS) rate of 80% and a progression-free survival (PFS) rate of 44%, which compare very favorably to historic median survival rates with standard of care alone. At a median analysis time of 32 months, 11 out of 16 patients in the trial were still alive (69%) and 6 out of 16 (38%) continued to be disease-free.
